Venture Houston 2018
Skip Content

13 April 2018

GlaxoSmithKline picks stake in Orchard

Orchard Therapeutics has licensed a range of gene therapies from GSK, which will get a 19.9% stake in the company as part of the deal.

Author: Thierry Heles, Reporter

Pharmaceutical firm GlaxoSmithKline (GSK) acquired a 19.9% stake in UK-based gene therapy developer Orchard Therapeutics yesterday as part of an agreement to license a portfolio of gene therapies to the company.